QLT (QLTI) Said The FDA To Review Aczone labeling supplement
More News related to QLTI
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Morning Movers 11/27: HEB, FAZ, QLTI Higher; ING, LYG, GNV, GAF Lower
- QLT Inc. (QLTI) Shares Higher as RBC Upgrades to Outperform
- Unusual 11 Mid-Day Movers 11/25: RTK, QADI, QBC, KBX Higher; BNHNA, DRAM, TBH, CWTR Lower
- QLT (QLTI) Settles Litigation with General Hospital of Massachusetts
More News related to FDA
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- Santarus (SNTS) Jumps Ahead of Expected News
- Hemispherx Biopharma (HEB) Receives Letter for Ampligen From US FDA; FDA Cannot Approve Application in Present Form
- Hemispherx (HEB) Falls 30% as FDA Recommends Another Ampligen Study, Says Can't Approve Application in Present Form
QLT Inc. (NASDAQ: QLTI) said the FDA has accepted for filing and review QLT USA, Inc.'s labeling supplement for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label. A decision by the FDA on the label revision is expected by the end of March 2008.
Related Categories
FDAStocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
